Table 1.
Baseline characteristics
| Placebo (n = 77) | Alirocumab 150 mg Q2W (n = 108) | |
|---|---|---|
| Age, mean (SD), years | 53.8 (9.4) | 58.2 (10.1) |
| Males, % | 49.4 | 43.5 |
| Race, % | ||
| White | 84.4 | 88.9 |
| Black or African American | 13.0 | 11.1 |
| Other | 2.6 | 0 |
| Body mass index, mean (SD), kg/m2 | 28.9 (4.7) | 29.2 (4.6) |
| Lipid parameters (determined by conventional methods), mean (SD), mg/dL | ||
| LDL-C | 130.6 (27.5) | 127.2 (25.0) |
| Total cholesterol | 210.5 (32.1) | 208.0 (30.5) |
| HDL-C | 51.8 (13.8) | 53.8 (15.0) |
| Non-HDL-C | 158.7 (30.8) | 154.2 (31.3) |
| Triglycerides, median (Q1:Q3) | 122.5 (91.5–174.0) | 123.5 (87.8–168.5) |
| Apolipoprotein B | 108.8 (22.8) | 108.1 (23.9) |
| Lipoprotein (a), median (Q1:Q3) | 19.0 (6.0–77.0) | 28.0 (9.0–70.0) |
Pooled patients from placebo and alirocumab 150 mg Q2W groups of three Phase II studies. To convert cholesterol values to mmol/L, multiply by 0.02586; to convert triglycerides to mmol/L, multiply by 0.01129
Q2W every 2 weeks, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, SD standard deviation